Monopar Therapeutics

Forecast & Rating13 analysts currently cover Monopar Therapeutics, with about 100.0% giving a positive rating — meaning they expect the stock to rise. The average price target is $116.85, about 6.3% upside from the current price of $109.87. Price targets span a fair range, indicating some disagreement among institutions. Historically, about 32.6% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Monopar Therapeutics closely still see room for the stock to rise. Data as of Jul 22, 2026; for reference only and not investment advice.